STRYKER CORP

Canaccord’s review cuts Stryker’s near‑term target but backs its long‑term value—highlighting supply‑chain hurdles, FDA pressure, but strong diversification, R&D and global reach.

Discover why Stryker Corp’s $105 B market cap, high‑margin orthopedics, and supply‑chain resilience make it a top long‑term medical‑technology investment.

Explore how Stryker’s operating margin, low revision rate and value‑based contracts shape the future of medical‑device pricing, market timing, and patient access.

Explore Stryker’s 28x P/E, 12% earnings CAGR, and supply‑chain gains—why investors see a 7‑20% upside despite rising valuation premiums.

Discover how Stryker’s SportSuite Vision, now FDA‑approved for Apple Vision Pro, is reshaping hip arthroscopy with real‑time AR, boosting workflow and patient safety.

Explore how Stryker’s recent cloud breach impacts patient data, regulatory compliance, and supply‑chain integrity—no immediate device risk, but long‑term effects remain unclear.

Explore how Stryker Corp. outpaced the medical‑device sector in Q2 2026, beating earnings estimates, managing a cyber‑attack, and driving growth across MedSurg, neurotech, and orthopedics.

UBS urges investors to shift from AI‑heavy tech to low‑volatility, earnings‑resilient firms—utilities, staples, and healthcare—to weather geopolitical shocks, regulation and inflation.

Discover Stryker’s Pangea Plating System—now CE‑marked in Europe—offering precise, variable‑angle fixation, reduced operative time, and proven safety for complex fractures.

Explore how Stryker’s latest RSU share‑holding adjustments align executive ownership with shareholder value, boosting governance transparency and industry‑wide best practices.